Structures of human PTP1B variants reveal allosteric sites to target for weight loss therapy.
Aliki PerdikariVirgil A WoodsAli EbrahimKatherine L LawlerRebecca BoundsNathanael I SinghTamar Skaist MehlmanBlake T RileyShivani SharmaJackson W MorrisJulia M KeoghElana HenningMiriam SmithDavid R FitzPatrickDaniel A KeedyPublished in: bioRxiv : the preprint server for biology (2024)
Protein Tyrosine Phosphatase 1B (PTP1B) is a negative regulator of leptin signaling whose disruption protects against diet-induced obesity in mice. We investigated whether structural characterization of human PTP1B variant proteins might reveal precise mechanisms to target for weight loss therapy. We selected 12 rare variants for functional characterization from exomes from 997 people with persistent thinness and 200,000 people from UK Biobank. Seven of 12 variants impaired PTP1B function by increasing leptin-stimulated STAT3 phosphorylation in cells. Using room-temperature X-ray crystallography, hydrogen-deuterium exchange mass spectrometry, and computational modeling, we determined that human variants modulate the 3-dimensional structure of PTP1B through distinct allosteric conduits that energetically link distal, highly ligandable structural regions to the active site. These studies inform the design of allosteric PTP1B inhibitors for the treatment of obesity.
Keyphrases
- weight loss
- endothelial cells
- room temperature
- copy number
- bariatric surgery
- small molecule
- mass spectrometry
- induced pluripotent stem cells
- metabolic syndrome
- type diabetes
- insulin resistance
- roux en y gastric bypass
- high resolution
- pluripotent stem cells
- genome wide
- induced apoptosis
- oxidative stress
- minimally invasive
- stem cells
- cell proliferation
- gene expression
- transcription factor
- body mass index
- adipose tissue
- dna methylation
- skeletal muscle
- magnetic resonance
- bone marrow
- high performance liquid chromatography
- physical activity
- replacement therapy
- endoplasmic reticulum stress
- mesenchymal stem cells
- combination therapy
- smoking cessation
- tandem mass spectrometry
- case control